Learnings about the complexity of extracellular tau aid development of a blood‐based screen for Alzheimer's disease
Zhicheng Chen(Zhongda Hospital Southeast University), Dominic M. Walsh(Biogen (United States)), Michael S. Perkinton(AstraZeneca (United Kingdom)), Robert A. Rissman(University of Southern California), Andrew Billinton(AstraZeneca (United Kingdom)), Ashvini Keshavan(University College London), David Mengel(German Center for Neurodegenerative Diseases), Reisa A. Sperling(Harvard University), Jennifer Percival‐Alwyn(AstraZeneca (United Kingdom)), Douglas Galasko(University of Minnesota), Purvish P. Patel(Quanterix (United States)), Henrik Zetterberg(University of Wisconsin–Madison), Michael J Properzi(Massachusetts General Hospital), Dennis J. Selkoe(Brigham and Women's Hospital), Keith A. Johnson(Brigham and Women's Hospital), Jonathan M. Schott(UK Dementia Research Institute), Aaron P. Schultz(Harvard University)
Cited by 119
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k